Wearable Defibrillator Market: Breaking a 20-Year Monopoly

On July 14, Kestra Medical Technologies announced two significant milestones. The company reported $95.1 million in fiscal 2026 revenue, representing 59% year-over-year growth, and secured up to $200 million in non-dilutive financing from Pharmakon Advisors.

Those announcements represent more than another successful financing. They suggest one of the fastest-growing companies in the wearable defibrillator market now has the resources to challenge one of medtech’s longest-standing competitive positions.

For nearly two decades, ZOLL’s LifeVest has dominated the wearable cardioverter defibrillator (WCD) category. Kestra’s accelerating commercial performance, combined with substantial non-dilutive capital, signals that the market may finally be entering a new phase.

The Wearable Defibrillator Market Is Becoming Competitive

Wearable cardioverter defibrillators provide temporary protection for patients at elevated risk of sudden cardiac death. Patients recovering from a heart attack or newly diagnosed with cardiomyopathy often wear these devices while physicians determine whether permanent therapy is necessary.

For years, the category remained largely unchanged.

The global WCD market is valued at approximately $298 million in 2026 and is projected to reach $535 million to $583 million by 2033. ZOLL’s LifeVest accounts for roughly 45% of global revenue and has operated with limited direct competition in the United States throughout most of its history.

Kestra’s ASSURE system is emerging as the strongest challenger. During fiscal 2026, the company reported 59% revenue growth, 57% growth in ASSURE prescriptions to 20,720, gross margin expansion from 40.5% to 51.4%, and its tenth consecutive quarter of margin improvement. The company also guided to approximately $137 million in revenue for the coming fiscal year.

Historically, broader adoption of WCDs has been constrained by two factors: garments that many patients found difficult to wear consistently and ongoing debate surrounding clinical effectiveness. Both dynamics are beginning to shift as new products enter the market.

Why Wearability Has Become the Defining Competitive Advantage

A wearable defibrillator can only deliver therapy if the patient is wearing it when a life-threatening arrhythmia occurs. Compliance is not simply an operational metric; it directly determines whether the technology can save a life.

That reality has made wearability the primary battleground.

Kestra’s ASSURE system is approximately 30% lighter than conventional garments and has gained traction among pediatric and active patients.

Element Science has taken an even different approach. Its FDA-approved Jewel system replaces the traditional vest with an adhesive patch and achieved median wear times exceeding 23 hours per day during its pivotal clinical trial.

After two decades of relatively limited innovation, the WCD market is finally competing on the characteristic that matters most: whether patients will consistently wear the device.

Why Kestra Chose Debt Instead of Equity

Kestra’s financing consists of a five-year senior secured term loan providing $75 million at closing, which was used in part to retire the company’s existing $45 million term loan. Additional tranches of $25 million and $50 million are available at Kestra’s option, with the larger tranche becoming available once the company reaches $150 million in trailing twelve-month revenue. The agreement also includes a separate $50 million uncommitted acquisition tranche, subject to Pharmakon’s approval, while providing 48 months of interest-only payments.

For a company growing revenue by 59% while continuing to expand margins, non-dilutive debt allows management to fund growth without issuing additional equity. The structure also reflects a broader trend LSI has highlighted in recent months, with several of medtech’s largest financings favoring debt over equity as companies preserve shareholder value while public market multiples remain compressed.

LSI’s Perspective

This announcement reinforces two themes that continue to shape medtech.

The first is the strength of incumbent market leaders. ZOLL has spent decades building the WCD category, and its fifth-generation LifeVest reports a 97% first-shock success rate. Market leadership of that scale is difficult to disrupt.

The second is the importance of well-capitalized challengers. A differentiated product alone rarely changes an established market. Combining a differentiated product with significant financial resources creates a much more credible competitive threat.

The most meaningful outcome, however, may benefit the category as a whole. If more comfortable devices improve patient compliance, stronger outcomes data could encourage broader physician adoption and expand the overall market rather than simply shifting share between competitors.

Compass AI’s Predictions

Compass AI’s Prediction Agent (a Beta capability) fuses LSI's proprietary intelligence (i.e., the millions of data points across our library of executive talks, interviews, research, and editorial content) with the live company and deal data in our database.

Here’s what our Agent predicts:

1. Element Science becomes an acquisition target. Compass AI believes a major cardiac rhythm management company, such as Boston Scientific, Medtronic, or Abbott, could acquire Element Science within the next 18 months as the wearable defibrillator market becomes increasingly competitive.
2. ZOLL responds aggressively. Expect the market leader to answer with a lighter device, a patch-style alternative, more aggressive pricing, or a combination of those strategies as new competitors gain momentum.
3. Kestra expands beyond WCDs. The financing’s dedicated acquisition tranche suggests the company intends to build a broader cardiac monitoring and therapy platform rather than remain a single-product company.

Final Thoughts

Kestra’s financing is about more than strengthening its balance sheet. It provides one of the industry’s fastest-growing challengers with the resources to compete in a category that has seen little meaningful competition for two decades. If improved product design increases patient compliance and strengthens clinical evidence, the biggest winner may ultimately be the wearable defibrillator market itself, with broader adoption creating a larger opportunity for every participant.